AP. Alltracel PH.

RNS Number:2584W
Alltracel Pharmaceuticals Plc
09 May 2007

                         Alltracel Pharmaceuticals Plc.

        -       Appointment of Nick Hart as CFO and Executive Director -



Wednesday 9th May 2007: Dublin, Ireland and London, UK




The Board of Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"),
(AIM:AP.L), the Healthcare Innovation Group focused on the Wound Care, Oral Care
and Cardiovascular Health markets, are pleased to announce today the appointment
of Mr. Nick Hart as CFO and executive director to the Board.  His role will
focus primarily on corporate activities including mergers and acquisitions. Nick
will be based at the Company's London offices.



Nick has worked in the Life Sciences sector for over twenty years and has
extensive experience in completing corporate transactions, including licensing,
business development and M&A.



Before joining Alltracel, Nick worked as CFO of Smart Holograms Ltd, a company
developing devices for disease diagnosis and management, and for Bioscience
Managers Ltd, an international Life Sciences corporate finance and advisory
practice, advising companies on M&A, strategy, and licensing transactions.
Prior to this he was CFO, COO and then acting CEO of Cantab Pharmaceuticals plc,
where he led the merger with Xenova Group plc, both UK biotechnology companies.
He has also worked for BOC Healthcare and Servier, a French pharmaceutical
company.



We also announce today the resignation of Mr. Irial Finan from the Board. Irial
served as a non-executive director since January 2004 and contributed invaluable
advice and experience over the past few years during Alltracel's international
expansion.  He has decided to step down from the Board due to the increased
demands of his executive commitments within the Coca Cola Group.



Further changes include the current Group Financial Controller Stuart Sands
assuming Company Secretarial duties following the departure of John Fitzpatrick
as Finance Director and Secretary.  We would like to thank John for his
contribution to the Company over the last 19 months and wish him well in his
return to practice.



Commenting on these developments, Padraic O'Connor, Chairman of Alltracel said:



''On behalf of the Board and the Company, I would like to extend a warm welcome
to Nick Hart whose Life Sciences background and deal experience will assist in
our strategy to grow the Alltracel Group in its core markets and to explore new
markets.  I would also like to express our appreciation to Irial for his
contribution to the Company's growth and success over the past number of years."



Nick (52) is a director of ProSpect Pharma Inc and was a director of Smart
Holograms Ltd and Bioscience Managers Ltd.  There are no further disclosures to
be made in respect of Nick Hart under paragraph g of Schedule 2 of the AIM Rules
for Companies.



                                      Ends



For Further Information Contact:


Dublin: Denise Cronin                        Alltracel: +353 1 235 2162
                                             press@alltracel.com
London: Deborah Scott                        Financial Dynamics: +44 207 831 3113
New York: Sean Leous                         Financial Dynamics: +1 212 850 5626



Notes to Editors:

Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.



Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.



With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.



Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:



Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovation technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, and Cardiovascular Health.



* Alltracel's specialist Oral Care subsidiary Westone (www.westoneproducts.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands internationally.



* Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of NanospiderTM technology for the global
healthcare market.



Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas.



m*docTM is a trademark of Alltracel Pharmaceuticals plc.



NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAUWUBRBRRVRAR

Alltracel Pharmaceuticals (LSE:AP.)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Alltracel Pharmaceuticals (LSE:AP.)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025